Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGENGet Rating) in a research note issued on Friday. The brokerage set a “hold” rating on the stock.

Shares of Oragenics stock opened at $0.24 on Friday. The company has a market cap of $27.75 million, a PE ratio of -1.70 and a beta of 0.12. Oragenics has a 1 year low of $0.22 and a 1 year high of $1.15. The stock has a 50-day moving average price of $0.35.

Oragenics (NYSE:OGENGet Rating) last issued its earnings results on Thursday, March 24th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $0.09 million during the quarter.

Oragenics Company Profile (Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Featured Stories

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.